Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
Close

Search

Subscribe
Pill to treat pancreatic cancer hailed as 'biggest breakthrough in decades' | Pancreatic cancer
Health

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’ | Pancreatic cancer

Stephen Atcheler
By Stephen Atcheler
November 20, 2026 3 Min Read
Comments Off on Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’ | Pancreatic cancer

A pill that can shrink and potentially eliminate pancreatic tumors is being hailed as the most revolutionary cancer treatment in decades.

In one in 12 patients who received the drug, daraxonrasib, during a trial, the cancer became undetectable and the tumors stopped growing in almost all 61 patients. Trial participants had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

Although doctors said the pill cannot yet be considered a cure, and they do not know how long it can keep the disease at bay, they said it is encouraging news because it appears it would offer patients more time, even if it does not lead to complete remission.

Half of people diagnosed with pancreatic cancer die within three months, and only about 3 percent of patients survive five years when the disease spreads to other organs. It has the lowest survival rate of all common cancers in the UK and has an equally poor prognosis globally.

Patients were followed for an average of a year and a half during the trial and some did not see the cancer return during this time. Longer studies will be conducted to see if any of the cancers can be put into remission. During the trial, tumors stopped growing in 90% of patients, just over 60% of patients saw their tumors shrink or disappear, and in about 8% of patients, tumors became undetectable on CT scan.

One year after the start of treatment, 76.6% of patients were alive; typically, 40 to 45% of patients receiving chemotherapy alone survive one year.

Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who presented the results, said “this is the closest we’ve come to a cure,” adding that he had never seen so many tumors disappear in patients whose cancer had spread.

He presented the results at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. “We are starting to see not only a higher percentage tumor response rate, but also deeper responses and a near doubling of the duration of disease control, which could eventually translate into longer survival,” he said.

“The median follow-up is 18 months. Imagine, in 18 months on average, your disease disappears on the scan… it’s the closest you can get to complete remission… it’s incredible.”

Daraxonrasib is a KRAS inhibitor treatment, which works by locking and disabling certain mutations found in most pancreatic cancers. These mutations lead to tumor growth.

It is hoped the treatment could work for dozens of other cancers, as they may have similar mutations.

Michelle Mitchell, chief executive of Cancer Research UK, said more research was needed, but added: “This is the biggest step forward we have seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult to treat cancers.

“These results raise the exciting possibility that this advance could potentially pave the way for the treatment of other cancers with Kras gene mutations. Further trials are now needed before this treatment can be evaluated for use on the NHS and despite this advance, survival for pancreatic cancer is still very low.”

Gn Health

Views: 3
Stephen Atcheler
Author

Stephen Atcheler

**Stephen** is a staff journalist at **DailyVoxa**, specializing in business, finance, technology, artificial intelligence, and global markets. He is committed to delivering timely, accurate, and insightful reporting that helps readers understand the forces shaping the global economy and the rapidly evolving digital landscape.Drawing on in-depth research and credible sources, Stephen covers breaking developments, industry trends, and emerging innovations with a focus on clarity, balance, and factual accuracy. His reporting is designed to provide readers with reliable information, practical context, and thoughtful analysis without sensationalism.As a member of the DailyVoxa editorial team, Stephen follows the publication's Editorial Policy, Fact-Checking Policy, Corrections Policy, and Ethics Policy. Every article is carefully reviewed to ensure it meets the highest standards of journalistic integrity, transparency, and editorial independence.

Follow Me
Other Articles
Stocks Making the Biggest Premarket Moves: Anthropic, Ross Stores, Gap and More - CNBC
Previous

Stocks Making the Biggest Premarket Moves: Anthropic, Ross Stores, Gap and More – CNBC

Russia hits 3 kyiv bridges after Putin vows to retaliate for attacks on popular bridge to Crimea
Next

Russia hits 3 kyiv bridges after Putin vows to retaliate for attacks on popular bridge to Crimea

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.
  • About Us
  • Accessibility Statement
  • Advertise With Us
  • AI Usage & Transparency Policy
  • Contact us
  • Cookie Policy
  • Corrections Policy
  • Meet Our Team
  • Privacy Policy
    • Disclaimer
    • DMCA & Copyright Policy
    • Editorial Policy
    • Ethics Policy
    • Fact-Checking Policy
  • Terms and Conditions
Copyright 2026 — Today's News. Tomorrow's Perspective.. All rights reserved.